Table 1.

Effects of drotrecogin on mortality in National Registry data

Registry/Trial	Country	Patients treated with DrotAA (% of cases)	ARR	OR (95% CI)
PROWESS	International	1,690	6.1%	0.8 (0.69 to 0.94)
	UK [21]	1,245 (6.3%)		0.75 (0.68 to 0.83)
	Poland [22]	302 (9.3%)	17.3%
PROGRESS	International [20]	882 (7%)		0.75 (0.63 to 0.9)
	Belgium [24]	430	12.8%	0.61 (0.40 to 0.92)

ARR, absolute risk reduction; CI, confidence interval; DrotAA, drotrecogin alfa (activated); OR, odds ratio; PROGRESS, Promoting Global Research Excellence in Severe Sepsis; PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis.